Matches in Wikidata for { <http://www.wikidata.org/entity/Q90857957> ?p ?o ?g. }
- Q90857957 description "article scientifique publié en 2018" @default.
- Q90857957 description "artículu científicu espublizáu n'agostu de 2018" @default.
- Q90857957 description "im August 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90857957 description "scientific article published on 06 August 2018" @default.
- Q90857957 description "wetenschappelijk artikel" @default.
- Q90857957 description "наукова стаття, опублікована в серпні 2018" @default.
- Q90857957 description "գիտական հոդված հրատարակված 2018 թվականի օգոստոսի 6-ին" @default.
- Q90857957 name "Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer" @default.
- Q90857957 name "Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer" @default.
- Q90857957 type Item @default.
- Q90857957 label "Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer" @default.
- Q90857957 label "Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer" @default.
- Q90857957 prefLabel "Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer" @default.
- Q90857957 prefLabel "Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer" @default.
- Q90857957 P1433 Q90857957-E24B1678-E1A4-4866-BD52-654C4AC4EB45 @default.
- Q90857957 P1476 Q90857957-EF3901C9-C24E-4874-96A5-ACD011C80B3F @default.
- Q90857957 P2093 Q90857957-2DF493DE-F2A3-4D4F-ABF5-E95442DD82DD @default.
- Q90857957 P2093 Q90857957-38B4C1C8-04AF-43AC-8EC4-4F921AD5D65B @default.
- Q90857957 P2093 Q90857957-42ABE65A-66F4-421E-8E5D-AC46606CB3A9 @default.
- Q90857957 P2093 Q90857957-60A5C800-1D46-4E1B-9A77-63206B7E8C8C @default.
- Q90857957 P2093 Q90857957-B0148C54-C66E-4376-975A-6E689278CE11 @default.
- Q90857957 P2093 Q90857957-F04FB2A9-338D-4CA1-87DD-AE1A2B31A743 @default.
- Q90857957 P2860 Q90857957-02B3F8C7-FD30-4C17-9403-D42E5D9012F1 @default.
- Q90857957 P2860 Q90857957-09C7A1DE-B155-4F3F-856D-DA9DB592D819 @default.
- Q90857957 P2860 Q90857957-0A076A92-AD8A-4587-AF3B-0C8A475F59CC @default.
- Q90857957 P2860 Q90857957-0DA59C6E-24AD-45D7-927F-241249801710 @default.
- Q90857957 P2860 Q90857957-0E1AC53F-B63B-4DED-8E10-8D41A49A6EB4 @default.
- Q90857957 P2860 Q90857957-1082694E-D30B-4E63-B13B-04158B0D65F6 @default.
- Q90857957 P2860 Q90857957-1F203EB7-A08A-49DC-9B80-3EEBB6FB0A39 @default.
- Q90857957 P2860 Q90857957-297C3C55-D502-46F5-9E1C-C3E6660F78FD @default.
- Q90857957 P2860 Q90857957-3230DD64-D235-4D82-9F25-92CA65C07C03 @default.
- Q90857957 P2860 Q90857957-37EC4676-AD3F-4009-83CB-A2FF70F8D1D4 @default.
- Q90857957 P2860 Q90857957-3F1CB3B7-447D-42C2-9760-E8817E739DA6 @default.
- Q90857957 P2860 Q90857957-40B5CCEC-732D-4945-B793-25EF0994559F @default.
- Q90857957 P2860 Q90857957-4E6D43F6-A884-429A-91A1-955AA22B22D7 @default.
- Q90857957 P2860 Q90857957-57B4BB2A-0C3B-432E-AFCD-2E9306D59D70 @default.
- Q90857957 P2860 Q90857957-66DB7554-45B0-481C-B8FF-9F16F61D85BB @default.
- Q90857957 P2860 Q90857957-66DC5AAA-AFE5-4159-9A64-18FCCA93DD18 @default.
- Q90857957 P2860 Q90857957-6A38216B-EB13-4976-BEA3-DA3D859D3FEC @default.
- Q90857957 P2860 Q90857957-83DA2A1F-98DA-43C5-A79B-FF6A23DD230E @default.
- Q90857957 P2860 Q90857957-888B85A0-B752-4663-B226-ACCA5ECBC820 @default.
- Q90857957 P2860 Q90857957-8AC804E8-0A67-4748-B924-6D4CEDA155B3 @default.
- Q90857957 P2860 Q90857957-91F3CB07-2413-40EA-8B46-EF0C34253B2A @default.
- Q90857957 P2860 Q90857957-937B8E5E-3FD9-4005-8FCF-EFE2D5909CF2 @default.
- Q90857957 P2860 Q90857957-9A61E8DD-4BC1-414A-B2C0-E9D28AFEF02D @default.
- Q90857957 P2860 Q90857957-9A925D27-4FDA-4868-B67E-AB0828D60865 @default.
- Q90857957 P2860 Q90857957-9AF0E737-805B-431D-A888-928D03DC1D11 @default.
- Q90857957 P2860 Q90857957-A04CD02E-6F8A-41A8-B896-29D7E06406F1 @default.
- Q90857957 P2860 Q90857957-D15FAFE2-86EE-4575-9AFA-F74E57B03E30 @default.
- Q90857957 P2860 Q90857957-D7CD1EBC-B85C-46C3-8110-4BC84C86AC2C @default.
- Q90857957 P2860 Q90857957-DD3BC505-6444-4F56-AE4B-3C48AEECA4B7 @default.
- Q90857957 P2860 Q90857957-E63D9B45-8910-419B-99AA-0F52D8963B41 @default.
- Q90857957 P2860 Q90857957-E73AFC23-E130-4D85-9AC0-1085B120C057 @default.
- Q90857957 P2860 Q90857957-E787182E-15CA-4584-A181-33F78A03AFEC @default.
- Q90857957 P2860 Q90857957-EAB3BD61-56C9-463C-97F5-67EE9068AD37 @default.
- Q90857957 P2860 Q90857957-EBA4B974-EC50-4160-A5F4-D45F29E33FF5 @default.
- Q90857957 P2860 Q90857957-EC462610-20B1-425A-8032-95036BE23622 @default.
- Q90857957 P2860 Q90857957-ED17BB2C-9A3B-4AD2-8560-DED1725978FE @default.
- Q90857957 P2860 Q90857957-F7ACCD32-7665-4960-B886-1C17A1451A36 @default.
- Q90857957 P2860 Q90857957-F7C6C2A3-DB83-429D-8C18-9947041A9428 @default.
- Q90857957 P2860 Q90857957-F97F1592-C8AA-45C2-A9D4-682D194A318F @default.
- Q90857957 P304 Q90857957-D95DB9EF-96BA-4D63-B770-511B65AC7CDD @default.
- Q90857957 P31 Q90857957-67D94561-F835-4022-8186-1B9F1497BF85 @default.
- Q90857957 P356 Q90857957-5B84D41B-BC25-42A6-A5F9-C323A58A79C8 @default.
- Q90857957 P433 Q90857957-931CD147-BFD3-4FA8-9F43-D8BE1AB5E75C @default.
- Q90857957 P478 Q90857957-929559E0-177B-4D6F-A705-D5A78AC4F485 @default.
- Q90857957 P50 Q90857957-0F4DC9BE-2885-4EEB-9136-868FFF8180DD @default.
- Q90857957 P577 Q90857957-FEB71013-8906-4A69-9782-ED6104497EF2 @default.
- Q90857957 P698 Q90857957-F4D8FB92-B50A-41C1-8BE1-22096B568F71 @default.
- Q90857957 P921 Q90857957-34B5C8B0-6724-4D04-9C3A-651A8BC71037 @default.
- Q90857957 P921 Q90857957-B3478329-D5EB-436F-A528-EF5937E863AE @default.
- Q90857957 P921 Q90857957-C5972828-D9D4-46B0-B46E-207CC2B96A55 @default.
- Q90857957 P356 J.YGYNO.2018.07.017 @default.
- Q90857957 P698 30093227 @default.
- Q90857957 P1433 Q5625182 @default.
- Q90857957 P1476 "Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer" @default.
- Q90857957 P2093 "Antonio Gonzalez-Martin" @default.
- Q90857957 P2093 "David M O'Malley" @default.
- Q90857957 P2093 "Karim Malek" @default.
- Q90857957 P2093 "Kathleen N Moore" @default.
- Q90857957 P2093 "Lainie P Martin" @default.
- Q90857957 P2093 "Michael J Birrer" @default.
- Q90857957 P2860 Q26828581 @default.
- Q90857957 P2860 Q26862249 @default.
- Q90857957 P2860 Q27692699 @default.
- Q90857957 P2860 Q28131668 @default.
- Q90857957 P2860 Q28543403 @default.
- Q90857957 P2860 Q33435836 @default.
- Q90857957 P2860 Q33856411 @default.
- Q90857957 P2860 Q34467788 @default.
- Q90857957 P2860 Q34502532 @default.
- Q90857957 P2860 Q34552660 @default.
- Q90857957 P2860 Q35749863 @default.
- Q90857957 P2860 Q36366709 @default.
- Q90857957 P2860 Q36433053 @default.
- Q90857957 P2860 Q36467605 @default.
- Q90857957 P2860 Q36822179 @default.
- Q90857957 P2860 Q36912991 @default.
- Q90857957 P2860 Q37254805 @default.
- Q90857957 P2860 Q37368055 @default.